Your browser doesn't support javascript.
loading
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
Le Bihan, Amélie; de Kanter, Ruben; Angulo-Barturen, Iñigo; Binkert, Christoph; Boss, Christoph; Brun, Reto; Brunner, Ralf; Buchmann, Stephan; Burrows, Jeremy; Dechering, Koen J; Delves, Michael; Ewerling, Sonja; Ferrer, Santiago; Fischli, Christoph; Gamo-Benito, Francisco Javier; Gnädig, Nina F; Heidmann, Bibia; Jiménez-Díaz, María Belén; Leroy, Didier; Martínez, Maria Santos; Meyer, Solange; Moehrle, Joerg J; Ng, Caroline L; Noviyanti, Rintis; Ruecker, Andrea; Sanz, Laura María; Sauerwein, Robert W; Scheurer, Christian; Schleiferboeck, Sarah; Sinden, Robert; Snyder, Christopher; Straimer, Judith; Wirjanata, Grennady; Marfurt, Jutta; Price, Ric N; Weller, Thomas; Fischli, Walter; Fidock, David A; Clozel, Martine; Wittlin, Sergio.
Affiliation
  • Le Bihan A; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • de Kanter R; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Angulo-Barturen I; GlaxoSmithKline, TresCantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos, Madrid, Spain.
  • Binkert C; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Boss C; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Brun R; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Brunner R; University of Basel, Basel, Switzerland.
  • Buchmann S; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Burrows J; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Dechering KJ; University of Basel, Basel, Switzerland.
  • Delves M; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Ewerling S; Medicines for Malaria Venture, Geneva, Switzerland.
  • Ferrer S; TropIQ Health Sciences B.V., Nijmegen, The Netherlands.
  • Fischli C; Department of Life Sciences, Imperial College London, SW7 2AZ, London, United Kingdom.
  • Gamo-Benito FJ; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Gnädig NF; GlaxoSmithKline, TresCantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos, Madrid, Spain.
  • Heidmann B; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Jiménez-Díaz MB; University of Basel, Basel, Switzerland.
  • Leroy D; GlaxoSmithKline, TresCantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos, Madrid, Spain.
  • Martínez MS; Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.
  • Meyer S; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Moehrle JJ; GlaxoSmithKline, TresCantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos, Madrid, Spain.
  • Ng CL; Medicines for Malaria Venture, Geneva, Switzerland.
  • Noviyanti R; GlaxoSmithKline, TresCantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos, Madrid, Spain.
  • Ruecker A; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Sanz LM; Medicines for Malaria Venture, Geneva, Switzerland.
  • Sauerwein RW; Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.
  • Scheurer C; Eijkman Institute for Molecular Biology, Jakarta, Indonesia.
  • Schleiferboeck S; Department of Life Sciences, Imperial College London, SW7 2AZ, London, United Kingdom.
  • Sinden R; GlaxoSmithKline, TresCantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos, Madrid, Spain.
  • Snyder C; TropIQ Health Sciences B.V., Nijmegen, The Netherlands.
  • Straimer J; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Wirjanata G; University of Basel, Basel, Switzerland.
  • Marfurt J; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Price RN; University of Basel, Basel, Switzerland.
  • Weller T; Department of Life Sciences, Imperial College London, SW7 2AZ, London, United Kingdom.
  • Fischli W; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Fidock DA; Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.
  • Clozel M; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.
  • Wittlin S; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.
PLoS Med ; 13(10): e1002138, 2016 Oct.
Article in En | MEDLINE | ID: mdl-27701420
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Plasmodium falciparum / Plasmodium vivax / Acrylamides / Antimalarials Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: PLoS Med Journal subject: MEDICINA Year: 2016 Type: Article Affiliation country: Switzerland
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Plasmodium falciparum / Plasmodium vivax / Acrylamides / Antimalarials Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: PLoS Med Journal subject: MEDICINA Year: 2016 Type: Article Affiliation country: Switzerland